CD6 and Sepsis: Another remarkable finding is CD6.PD3 peptide’s additive/synergistic effect on mice survival when coadministered with Imipenem/Cilastatin, a member of the carbapenem family considered as first-choice treatment in critical care patients undergoing sepsis (36).